Skip to content

    Doms Industries

    DOMS
    Fast Moving Consumer Goods·26 May 2025
    Management Summary

    Doms Industries delivered strong Q4 and FY25 results, with consolidated revenue growing 26% and 24.4% respectively, driven by consistent performance across core categories, new product launches, and Uniclan integration. The company maintained healthy EBITDA margins and saw PAT grow significantly. Strategic investments in capacity expansion, including the 44-acre plant and the acquisition of Super Treads, are underway to support future growth, while the Uniclan acquisition continues to integrate well.

    Highlights

    8
    • Q4 FY25 Consolidated Revenue from operations grew 26% YoY to INR 508 crores.

    • FY25 Consolidated Revenue from operations grew 24.4% YoY to INR 1,912 crores.

    • Q4 FY25 EBITDA grew 16.2% YoY to INR 88.3 crores, with a margin of 17.3%.

    • FY25 EBITDA grew 27.8% YoY to INR 348.4 crores, with a margin of 18.2%.

    • Q4 FY25 PAT grew 9.3% YoY to INR 51.3 crores, with a margin of 10.1%.

    • FY25 PAT grew 33.7% YoY to INR 213.5 crores, with a margin of 11.2%.

    • Board recommended a dividend of INR 3.15 per share.

    • Invested INR 213 crores in capex during FY25, with INR 113 crores for the 44-acre plant.

    What Changed2

    vs Q1 FY26

    Guidance items10 → 7 (-3)Risks discussed1 → 4 (+3)
    Key financials

    Metrics

    10

    Periods

    2

    Q4 FY25

    5
    • Revenue
      ₹508 Cr
      YoY+26%
    • EBITDA
      ₹88.3 Cr
      YoY+16.2%
    • EBITDA Margin
      17.3%
    • PAT
      ₹51.3 Cr
      YoY+9.3%
    • PAT Margin
      10.1%

    FY25

    5
    • Revenue
      ₹1,912 Cr
      YoY+24.4%
    • EBITDA
      ₹348.4 Cr
      YoY+27.8%
    • EBITDA Margin
      18.2%
    • PAT
      ₹213.5 Cr
      YoY+33.7%
    • PAT Margin
      11.2%

    Segment breakdown

    Core Stationery Business (ex-Uniclan)
    17% FY25 Growth
    Scholastic Stationery, Scholastic Art, Kits & Combos
    ₹1,360 Cr FY25 Gross Sales7.8% FY25 Growth3.5% FY25 Volume Growth3.5% FY25 ASP Increase
    Uniclan Healthcare
    ₹48.1 Cr Q4 FY25 Revenue₹15 Cr Current Monthly Run Rate₹17 Cr Current Monthly Run Rate Max8% EBITDA Margin9% EBITDA Margin Max
    Fine Art Products (Amariz)
    50% FY25 Growth
    Hobby and Craft (Fixy Fix)
    25% FY25 Growth
    List

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    ₹225 crores

    IPO proceeds (INR 165+ crores unutilized as of March 31) plus internal accruals. Debt if required, but not currently seen as significant.

    Dividend

    ₹3.15/share (final)

    M&A

    Super Treads Private Limited

    acquisition · announced · Consideration ₹NaN (cash)

    M&A

    Uniclan Healthcare

    acquisition · integrated

    Liquidity

    Liquidity disclosed

    Cash reserves from IPO are being utilized for expansion, leading to lower other income.

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Consolidated Revenue Growth
    18-20%
    Medium
    Profitability
    EBITDA Margin
    16.5-17.5%
    High
    Profitability
    PAT Margin
    ~10%
    High
    Capex
    Capex Spend
    INR 225-250 crores
    High
    Working Capital
    Working Capital Cycle
    ~55 days
    Medium
    Capacity
    Pencil Capacity
    Increase from 5.5 million to 8 million pencils per day
    High
    Capacity
    Paper Stationery Capacity (ex-acquisition)
    Increase by 15-17%
    High

    44-acre Plant First Building Possession

    By Q3 FY26 (current calendar year end)
    CurrentUnder construction
    TargetPossession of first building

    Why it matters

    Key milestone for major capacity expansion, indicating readiness for commercial production.

    our ongoing 44-acre expansion project construction is underway in full swing with anticipated possession of first building by Q3 FY'26 and beginning of commercial production slated in Q4 FY'26. (Page 4)

    How to verify

    capital_allocation.capex.purposes

    Risks & concerns

    4
    RiskSeverity

    Construction Delays due to Climatic Conditions

    Unexpected rains and climatic changes caused delays in construction for the 44-acre plant, leading to conservative guidance.Management acknowledged

    medium

    External Uncertainties in Export Markets

    Complex export environment, but FILA agreement helps smoothen expansion; US demand stable despite uncertainties.Management acknowledged

    medium

    PAT Margin Impact from Other Income & Amortization

    Lower other income (due to cash utilization for capex) and INR 4.5 crores annual amortization from Uniclan brand value will impact PAT margin.Management acknowledged

    medium

    Capacity Constraints

    Company expects to remain capacity constrained for the next few years, especially in pencils, despite ongoing additions.Management acknowledged

    medium

    Q&A highlights

    8

    “if you look at the growth of the core stationery business on a year-on-year basis, we have grown in this financial year by more than 17%, which is close to our targeted guidance of 18% to 20%.”

    Clarifies the underlying organic growth of the core business, distinguishing it from overall consolidated growth which includes acquisitions, and details where capacity was added and planned.

    asked by Mehul Desai (JM Financial)

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Financial Performance in Q4 and FY25

    Doms Industries delivered robust financial results for Q4 FY25 and the full fiscal year. Consolidated revenue from operations grew 26% YoY to INR 508 crores in Q4 FY25 and 24.4% YoY to INR 1,912 crores for FY25. This growth was attributed to consistent performance across core categories, successful new product launches, and the integration of Uniclan. The core stationery business (ex-Uniclan) grew over 17% in FY25, aligning with targeted guidance.

    02

    Profitability and Margin Trends

    EBITDA for Q4 FY25 increased by 16.2% to INR 88.3 crores, with a margin of 17.3%, slightly below Q4 FY24's 18.8%. For the full year, EBITDA grew 27.8% to INR 348.4 crores, expanding the margin to 18.2% from 17.7% in FY24. PAT for Q4 FY25 grew 9.3% to INR 51.3 crores, but the PAT margin dipped to 10.1% due to lower other income from cash utilization for capex and a non-cash amortization expense of INR 2.3 crores related to Uniclan's brand value.

    03

    Strategic Capacity Expansion and Capex

    The company invested INR 213 crores in capital expenditure during FY25, with INR 113 crores allocated to the 44-acre expansion project and INR 100 crores to core stationery. For FY26, Doms plans to invest INR 225-250 crores primarily for building construction at the 44-acre facility and new land parcels. The first building at the 44-acre plant is expected to be ready by Q3 FY26, with commercial production slated for Q4 FY26, and funding primarily from IPO proceeds and internal accruals.

    04

    Impact of Acquisitions and Integration

    The Uniclan Healthcare acquisition has delivered positive results, contributing INR 48.1 crores in Q4 FY25 revenue with an 8-9% EBITDA margin. The company is actively integrating Uniclan's network with DOMS channels, reaching approximately 35,000 retail outlets. Additionally, Doms acquired a 51% stake in Super Treads Private Limited for INR 6 crores to bolster paper stationery manufacturing and improve reach in Eastern markets, with a potential monthly sales of INR 2.5-3 crores at full capacity.

    05

    Product Portfolio and Distribution Focus

    The company continues to focus on broadening its product portfolio and scaling its distribution network. Scholastic Stationery, Art, and Kits & Combos grew 7.75% in FY25, primarily from efficiency gains as new pencil capacity is still under construction. Significant growth was also seen in office supplies and paper stationery due to added capacities. Doms is prioritizing domestic market growth and distribution network expansion, while leveraging the FILA agreement for export expansion into developed markets.

    06

    Dividend Recommendation and Working Capital Management

    The Board recommended a dividend of INR 3.15 per share, subject to shareholder approval. The working capital cycle increased to around 60 days in FY25, mainly due to higher debtors from Uniclan integration and extended credit periods for channel partners in paper stationery. Management aims to reduce this to around 55 days with full Uniclan integration and growing operations.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.